Painchek (ASX:PCK) — Material Events
ASX:PCK · 16 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
PainChek Breaks Ground with FDA Clearance and US Market LaunchHigh
PainChek secures FDA clearance, launches US market entry with strong ARR growth and Infant App expansion
26 Nov 2025
·AGM Presentation
·90
PainChek’s FDA Clearance Unlocks $175M US Market and Infant App GrowthHigh
PainChek secures FDA clearance, expands US market access, and advances Infant App commercialization
31 Oct 2025
·Quarterly Activities and Cashflow Report
·90
PainChek Unlocks US$3bn RTM Market with FDA-Backed Reimbursement WinHigh
PainChek gains FDA-regulated status enabling US RTM reimbursement, unlocking multi-billion-dollar market opportunity
29 Jan 2026
·ASX Announcement
·90
PainChek posts growth but auditor flags material uncertainty over going concernHigh
PainChek grows recurring revenue and US market access but flags going concern uncertainty
23 Sept 2026
·Annual Report
·Unexpected
·88
PainChek Accelerates US Rollout with First Sabra Deployments and 5.9% ARR GrowthMedium
PainChek reports 5.9% ARR growth, first US commercial deployments, and improved cash flow
29 July 2026
·Quarterly Activities Report and Appendix 4C
·85
PainChek Secures FDA Clearance, Unlocking US $3bn RTM Market OpportunityMedium
PainChek gains FDA clearance for US RTM reimbursement, expands US market presence with strong global licence growth
30 Jan 2026
·Quarterly Activities and Cashflow Report
·85
PainChek Lands Major $5B Sabra REIT Deal for 20,000 North American BedsMedium
PainChek Secures Landmark Agreement with Sabra REIT for 20,000 Bed Deployment in North America
14 Apr 2026
·Commercial Agreement
·85
PainChek Secures FDA Clearance, Eyes US Market with $5.6M ARR GrowthHigh
PainChek achieves FDA clearance, expands US market entry, and grows ARR to $5.6M with Infant app launch
31 Oct 2025
·Quarterly Activities Report
·85
PainChek Secures FDA Clearance, Eyes US Market Despite Rising LossesMedium
PainChek reports half-year loss of AUD 4.7M; FDA clearance opens US market
27 Feb 2026
·Appendix 4D Half Year Report
·80
PainChek Raises A$5.5 Million Convertible Note to Fuel US GrowthMedium
PainChek raises A$5.5 million via convertible notes to fund US expansion and working capital
22 May 2026
·Capital Raising
·80
PainChek turns two Sabra sites into 23 US communitiesMedium
PainChek expands Sabra contracts to 23 US communities with 808 licences
13 Oct 2026
·Commercial Contract Expansion
·78
PainChek Names Karen Holzberger CEO to Accelerate US ExpansionMedium
PainChek appoints Karen Holzberger as CEO to drive US market growth
20 July 2026
·Executive Appointment
·75
PainChek Powers 9% UK Growth with 4,000 New Licenses in Aged CareMedium
PainChek achieves 9% quarterly growth in UK aged care with 4,000 new licenses
26 Mar 2026
·Operational Update
·75
PainChek Secures $1.123 Million R&D Refund to Boost US Market PushMedium
PainChek receives $1.123 million R&D tax incentive refund to support product development and US market entry
22 July 2026
·R&D Tax Incentive Refund Announcement
·60
PainChek CEO Philip Daffas Steps Down as US Expansion AcceleratesMedium
PainChek CEO Philip Daffas Steps Down; COO Andy Hoggan Named Interim CEO
6 July 2026
·Executive Leadership Change
·60
No articles in this tier for the last 12 months.
Market Mentions
9
- appeared in market wrap coverage
These are market wrap articles where Painchek (ASX:PCK) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 28 (6 July -> 10 July) 2026
11 July 2026
Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026